By Counterforce Health Team in Strensiq (asfotase alfa) —

How to Renew Strensiq (Asfotase Alfa) Approval with Humana in Georgia: Timeline, Documentation, and Appeals

Answer Box: Renewing Your Strensiq Coverage

Strensiq (asfotase alfa) prior authorization with Humana typically requires annual renewal with documented treatment response and continued medical necessity. In Georgia, start your renewal process 60-90 days before expiration to avoid treatment gaps. Your prescriber must submit updated clinical evidence, laboratory values, and radiographic improvements through Humana's provider portal or Clinical Pharmacy Review. If denied, Georgia residents have 60 days to request external review through the Georgia Department of Insurance.

First step today: Contact your prescriber to schedule renewal documentation review and confirm your current approval expiration date.

Table of Contents

Renewal Triggers: When to Start Early

Standard Renewal Timeline

Most Strensiq prior authorizations require annual renewal, though some Humana plans may approve shorter periods (6 months) for initial therapy or dose adjustments. Your approval letter will specify the exact expiration date.

Tip: Set a calendar reminder 90 days before expiration. Complex renewals can take 30+ days if additional documentation is needed.

Early Renewal Triggers

Start the renewal process immediately if you experience:

  • Dose escalation needs (up to 9 mg/kg/week for inadequate response)
  • New insurance plan enrollment (job change, Medicare transitions)
  • Formulary status changes (Strensiq moves from Tier 5 to non-formulary)
  • Provider network changes (your specialist leaves Humana's network)

Signs of Potential Renewal Issues

Contact Counterforce Health for assistance if you notice:

  • Previous appeals or coverage delays
  • Plan notifications about formulary changes
  • Requests for additional clinical documentation mid-year

Evidence Update Requirements

Treatment Response Documentation

Your prescriber must demonstrate objective clinical improvement since initial approval:

Response Measure Documentation Required Frequency
Radiographic Global Impression of Change (RGI-C) Score ≥+2 showing bone healing Every 12 months
Growth metrics Height/weight Z-scores, percentile improvements Every 6 months
Functional status 6-minute walk test, respiratory function As clinically indicated
Laboratory monitoring PTH, calcium (ALP levels not reliable due to drug interference) Every 3 months

Required Clinical Updates

  • Current diagnosis confirmation: ICD-10 codes for hypophosphatasia (E83.30-E83.39)
  • Genetic testing: Original ALPL mutation analysis (can reference previous results)
  • Adherence documentation: Injection site rotation, missed doses, adverse events
  • Monitoring plan: Ophthalmology exams, renal ultrasounds for ectopic calcifications

Renewal Documentation Packet

Core Documents Checklist

✓ Updated medical necessity letter from prescribing specialist
✓ Clinical progress notes from last 6-12 months
✓ Recent laboratory results (PTH, calcium, phosphorus)
✓ Radiographic imaging showing continued bone disease or improvement
✓ Original genetic testing (ALPL mutation confirmation)
✓ Treatment response summary with objective measures

Medical Necessity Letter Structure

Your prescriber should include:

  1. Patient identification and confirmed HPP phenotype (perinatal/infantile/juvenile-onset)
  2. Current clinical status with specific improvements since starting Strensiq
  3. Continued treatment rationale - why Strensiq remains necessary
  4. Monitoring plan for the next approval period
  5. Alternative therapy assessment - why no other options are appropriate
Clinician Corner: Reference FDA labeling requirements and document that supportive care alone is insufficient. Include specific RGI-C scores and growth velocity improvements where available.

Submission Timeline and Decision Windows

Humana Decision Timeframes

  • Standard review: 72 hours for routine renewals
  • Expedited review: 24 hours if clinically urgent
  • Complex cases: Up to 7 days if medical director review required

Optimal Submission Schedule

90 days before expiration: Begin gathering updated documentation
60 days before expiration: Submit complete renewal packet
30 days before expiration: Follow up if no decision received
7 days before expiration: Request expedited review to prevent gap

Submission Methods

  • Primary: Humana provider portal
  • Backup: Fax to Humana Clinical Pharmacy Review (verify current number with plan)
  • Phone support: 1-800-833-6917 for member assistance

If Coverage Lapses: Bridge Options

Immediate Actions for Treatment Gaps

No standard bridging therapies exist for hypophosphatasia - Strensiq is the only FDA-approved enzyme replacement therapy. If coverage lapses:

  1. Contact Alexion OneSource immediately at 1-888-765-4747 for emergency access programs
  2. Request expedited appeal with Humana (24-72 hour decision timeline)
  3. Document clinical urgency - risk of bone disease progression, fractures, or respiratory compromise

Manufacturer Support During Gaps

Alexion OneSource offers:

  • Transition supplies during insurance changes
  • Emergency fills for urgent clinical situations
  • Injection support and patient education during coverage disputes
Note: Therapy interruption can lead to rapid clinical deterioration. Unlike some biologics, there are no alternative treatments to bridge hypophosphatasia management.

Annual Plan Changes to Monitor

2025 Humana Formulary Status

Strensiq remains on Specialty Tier (Tier 5) for most Humana Medicare plans, requiring highest cost-sharing and prior authorization. Monitor Humana's drug list updates monthly for changes.

Potential Coverage Changes

  • Biosimilar competition: Currently none available, but monitor for future market entries
  • Formulary tier movements: Rare diseases typically maintain coverage but cost-sharing may change
  • Network pharmacy requirements: Specialty drugs may require specific pharmacy networks

Plan Transition Considerations

When changing Humana plans or insurers:

  • Request transition supplies (up to 31 days) under new plan
  • Transfer prior authorization documentation to new plan's medical director
  • Verify specialist network participation with new plan

Appeals Process for Georgia Residents

Internal Appeal with Humana

Timeline: 65 days from denial date
Decision deadline: 7 days standard, 72 hours expedited
Submission: Member portal, phone (1-800-833-6917), or mail with denial letter

Georgia External Review

If internal appeal fails, Georgia residents can request external review through the Georgia Department of Insurance:

Deadline: 60 days from final internal denial
Process: Submit application to Georgia DOI Consumer Services
Timeline: 30 business days standard, 72 hours expedited
Cost: Free to consumer

Required Appeal Documentation

  • Original denial letter and internal appeal decision
  • Complete medical records supporting medical necessity
  • Prescriber attestation of continued need for Strensiq
  • Evidence of treatment response and monitoring compliance
Georgia-Specific Resource: Contact Georgia DOI Consumer Services at 1-800-656-2298 for external review assistance and forms.

Personal Progress Tracker

Renewal Checklist Template

Current Approval Details:

  • Approval expiration date: ___________
  • Current dose: _____ mg/kg/week
  • Prescribing specialist: ___________
  • Last RGI-C score: ___________

Documentation Status: □ Medical necessity letter updated
□ Lab results (last 3 months)
□ Radiographic imaging (last 12 months)
□ Growth/functional assessments current
□ Genetic testing on file

Submission Tracking:

  • Renewal submitted date: ___________
  • Humana reference number: ___________
  • Expected decision date: ___________
  • Follow-up scheduled: ___________

Counterforce Health: Expert Coverage Support

Counterforce Health specializes in turning insurance denials into successful appeals for complex specialty medications like Strensiq. Their platform analyzes denial letters, plan policies, and clinical notes to create targeted, evidence-backed appeals that address payer-specific criteria. For hypophosphatasia patients facing coverage challenges, Counterforce Health can help navigate Humana's requirements and Georgia's appeal processes with documentation that meets both clinical standards and payer expectations.

Frequently Asked Questions

How long does Strensiq prior authorization renewal take with Humana?
Standard renewals take 72 hours, though complex cases requiring medical director review may take up to 7 days. Submit 60-90 days before expiration to avoid gaps.

What if my Strensiq dose needs to increase during the approval period?
Dose escalations (up to 9 mg/kg/week) require prior authorization modification. Your prescriber must document inadequate response to current dosing with objective measures.

Can I appeal a Strensiq renewal denial in Georgia?
Yes. Georgia residents have 65 days for internal appeals with Humana, followed by 60 days for external review through the Georgia Department of Insurance at no cost.

What laboratory tests are required for Strensiq renewal?
Monitor PTH, calcium, and phosphorus levels. Avoid using alkaline phosphatase (ALP) levels due to drug interference - inform labs of Strensiq use for accurate testing.

Does Humana cover Strensiq for adult-onset hypophosphatasia?
Coverage is typically restricted to perinatal/infantile/juvenile-onset HPP. Adult-onset requires documentation of pediatric disease progression and genetic confirmation.

What happens if I miss my Strensiq renewal deadline?
Contact Alexion OneSource (1-888-765-4747) immediately for emergency access programs while pursuing expedited appeal with Humana.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Coverage policies vary by plan and change frequently. Always verify current requirements with your insurer and consult your healthcare provider for medical decisions. For additional support with insurance appeals in Georgia, contact the Georgia Department of Insurance Consumer Services at 1-800-656-2298.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.